Lantheus Holdings, Inc. $LNTH Shares Sold by Federated Hermes Inc.

Federated Hermes Inc. decreased its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 8.1% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 286,748 shares of the medical equipment provider’s stock after selling 25,413 shares during the period. Federated Hermes Inc. owned 0.42% of Lantheus worth $23,473,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in LNTH. Elevation Point Wealth Partners LLC purchased a new position in Lantheus in the second quarter valued at approximately $26,000. Quarry LP increased its position in shares of Lantheus by 2,350.0% in the first quarter. Quarry LP now owns 490 shares of the medical equipment provider’s stock worth $48,000 after acquiring an additional 470 shares in the last quarter. EverSource Wealth Advisors LLC raised its stake in shares of Lantheus by 190.2% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,065 shares of the medical equipment provider’s stock valued at $87,000 after acquiring an additional 698 shares during the period. EMC Capital Management purchased a new position in shares of Lantheus in the 2nd quarter valued at $93,000. Finally, Parkside Financial Bank & Trust lifted its holdings in shares of Lantheus by 20.2% during the 2nd quarter. Parkside Financial Bank & Trust now owns 1,264 shares of the medical equipment provider’s stock valued at $103,000 after acquiring an additional 212 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Down 2.2%

Shares of NASDAQ:LNTH opened at $60.88 on Wednesday. The firm has a market cap of $4.04 billion, a PE ratio of 25.58 and a beta of -0.10. The company has a fifty day simple moving average of $55.92 and a 200 day simple moving average of $63.25. The company has a current ratio of 2.67, a quick ratio of 2.49 and a debt-to-equity ratio of 0.51. Lantheus Holdings, Inc. has a 12-month low of $47.25 and a 12-month high of $111.29.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Tuesday, May 17th. The medical equipment provider reported $0.05 EPS for the quarter. The firm had revenue of $92.51 million for the quarter. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. On average, equities research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. The Goldman Sachs Group set a $77.00 price objective on Lantheus and gave the stock a “neutral” rating in a research note on Wednesday, October 8th. Truist Financial reissued a “hold” rating and set a $61.00 price target (down from $63.00) on shares of Lantheus in a research report on Monday, November 10th. B. Riley decreased their price target on Lantheus from $109.00 to $84.00 and set a “buy” rating for the company in a report on Tuesday, September 16th. Weiss Ratings lowered shares of Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Saturday, October 25th. Finally, TD Cowen decreased their target price on shares of Lantheus from $95.00 to $80.00 and set a “buy” rating for the company in a research note on Monday, September 15th. Four research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $74.17.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.